Pharmacotherapy of schizophrenia.
D000166:Acridines / Q000627:therapeutic use; D000284:Administration, Oral; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002090:Butyrophenones / Q000008:administration & dosage / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000139:chemically induced; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D008972:Molindone / Q000627:therapeutic use; D010640:Phenothiazines; D008517:Phytotherapy; D010879:Piperazines / Q000627:therapeutic use; D010946:Plants, Medicinal; D011926:Rauwolfia / Q000008:administration & dosage / Q000627:therapeutic use; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D012640:Seizures / Q000139:chemically induced; D013329:Structure-Activity Relationship; D013747:Tetrabenazine / Q000627:therapeutic use; D013892:Thioxanthenes / Q000008:administration & dosage / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014805:Vitamin B 12 / Q000008:administration & dosage
D000166:Acridines; D014150:Antipsychotic Agents; D002090:Butyrophenones; D010640:Phenothiazines; D010879:Piperazines; D013892:Thioxanthenes; D014149:Tranquilizing Agents; D014805:Vitamin B 12; D008972:Molindone; D004298:Dopamine; D013747:Tetrabenazine